CT SB00182

Reduces step therapy duration limits from 30 to 20 days for all prescribed drugs under both individual and group health insurance policies, effective January 1, 2025.

Prohibits step therapy requirements for cancer treatment drugs used for stage IV metastatic cancer and mental/behavioral health conditions (schizophrenia, major depressive disorder, bipolar disorder from January 1, 2024-2027; all mental/behavioral health conditions from January 1, 2025 onward).

Prohibits step therapy requirements for chronic, disabling, or life-threatening condition treatments starting January 1, 2025, provided drugs comply with FDA-approved indications.

Requires health carriers to establish and disclose convenient override processes allowing treating providers to request expedited step therapy exemptions when the required drug has been ineffective, is expected to be ineffective, would cause adverse reactions, or is not in the patient's best interest.

Prohibits requiring patients to obtain prescription drugs from mail order pharmacies as a condition of receiving benefits.